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Abstract
BACKGROUND/AIM: Several risk factors have been suggested for osteoporosis which frequently
occurs in inflammatory bowel disease (IBD) patients. We studied prevalence and risk factors for
reduced bone mineral density (BMD) in IBD patients at the University Hospital of Zurich, Switzerland.
METHODS: The BMD was determined by dual-energy X-ray absorptiometry at the lumbar spine and
femoral neck in 88 IBD patients (55 with Crohn's disease, 30 with ulcerative colitis, and 3 with
indeterminate colitis). Z scores were obtained by comparison with age- and sex-matched normal values,
and T scores by comparison with sex-matched healthy young adults. Osteopenia and osteoporosis were
defined according to the WHO guidelines. Predictive factors for BMD were analyzed by group
comparison and stepwise regression analysis. RESULTS: Osteopenia was present in 43% of the patients
at the lumbar spine and in 42% of them at the femoral neck. Osteoporosis was present in 14% of the
patients at the lumbar spine and in 5% of them at the femoral neck. At the lumbar spine, stepwise
regression analysis showed that body mass index, age, number of bowel resections, topic steroids, and
azathioprine correlated with the Z scores. Cumulative steroid dose, topic steroids, age and bowel
resection were found to be predictors for a pathological T score. At the femoral neck, regression analysis
showed that body mass index, age, topic steroids, and azathioprine correlated with the Z scores. Only a
low body mass index was a significant predictor for pathological femoral T scores. CONCLUSIONS:
Osteopenia and osteoporosis are commonly found in IBD patients. Steroid treatment and bowel
resection were significant risk factors for osteoporosis of the lumbar spine. However, disease-inherent
factors also appear to confer a major risk, indicating that the BMD should be determined in all IBD
patients, irrespective of steroid treatment.
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gression analysis showed that body mass index, age, 
number of bowel resections, topic steroids, and azathio-
prine correlated with the Z scores. Cumulative steroid 
dose, topic steroids, age and bowel resection were found 
to be predictors for a pathological T score. At the femoral 
neck, regression analysis showed that body mass index, 
age, topic steroids, and azathioprine correlated with the 
Z scores. Only a low body mass index was a signifi cant 
predictor for pathological femoral T scores.  Conclusions: 
Osteopenia and osteoporosis are commonly found in 
IBD patients. Steroid treatment and bowel resection 
were signifi cant risk factors for osteoporosis of the lum-
bar spine. However, disease-inherent factors also appear 
to confer a major risk, indicating that the BMD should be 
determined in all IBD patients, irrespective of steroid 
treatment. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Several studies have reported an increased risk for low 
bone mineral density (BMD) in patients with inﬂ amma-
tory bowel disease (IBD), with a prevalence of osteopo-
rosis reported in up to 37% of them  [1] . It is generally 
accepted that osteoporosis in IBD has a multifactorial 
pathogenesis, with potential risk factors such as reduced 
food intake, low body mass index (BMI), malabsorption 
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 Abstract 
 Background/Aim: Several risk factors have been sug-
gested for osteoporosis which frequently occurs in in-
fl ammatory bowel disease (IBD) patients. We studied 
prevalence and risk factors for reduced bone mineral 
density (BMD) in IBD patients at the University Hospital 
of Zürich, Switzerland.  Methods: The BMD was deter-
mined by dual-energy X-ray absorptiometry at the lum-
bar spine and femoral neck in 88 IBD patients (55 with 
Crohn’s disease, 30 with ulcerative colitis, and 3 with in-
determinate colitis). Z scores were obtained by compar-
ison with age- and sex-matched normal values, and T 
scores by comparison with sex-matched healthy young 
adults. Osteopenia and osteoporosis were defi ned ac-
cording to the WHO guidelines. Predictive factors for 
BMD were analyzed by group comparison and stepwise 
regression analysis.  Results: Osteopenia was present in 
43% of the patients at the lumbar spine and in 42% of 
them at the femoral neck. Osteoporosis was present in 
14% of the patients at the lumbar spine and in 5% of them 
at the femoral neck. At the lumbar spine, stepwise re-
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and vitamin D deﬁ ciency, small bowel resection, hypo-
gonadism, corticosteroid treatment  [2] , smoking  [3] and 
genetic factors  [4] . Crohn’s disease (CD) itself also seems 
to be an important risk factor for low BMD  [5] . A low 
BMD may already be present at the time of initial diag-
nosis of CD  [6] . CD patients without previous treatment 
appear to have a signiﬁ cantly lower average BMD of the 
lumbar vertebrae when compared with ulcerative colitis 
(UC) patients  [7] . Furthermore, the BMD in CD patients 
increases after induction of remission by azathioprine  [8] . 
These ﬁ ndings suggest that CD itself plays an important 
role in the development of osteopenia/osteoporosis, and 
that a low BMD cannot be attributed solely to treatment 
with steroids. Corticosteroids have been shown to reduce 
the BMD  [2, 9–16] , although the data are conﬂ icting  [5, 
6, 17–21] . 
 IBD patients have up to 40% more fractures than the 
general population  [22] , with an increased risk of both 
vertebral and hip fractures  [23] . Analysis of the risk fac-
tors for the development of osteoporosis could help to 
identify those IBD patients who have a higher risk of frac-
tures. We therefore aimed at analyzing the risk factors for 
a low BMD in our cohort of unselected IBD patients, so 
as to optimize BMD monitoring and treatment in at-risk 
patients. 
 Patients and Methods 
 Study Design and Patients  
 The study was a cross-sectional analysis of a local IBD cohort. 
At the time of analysis, 137 patients were registered in the IBD co-
hort of the University Hospital of Zürich. All patients were diag-
nosed by a combination of radiology, endoscopy, and histology. 
BMD was determined by dual-energy X-ray absorptiometry 
(DEXA) in 88 (64%) patients (55 CD, 30 UC, 3 indeterminate coli-
tis). Only patients with isolated proctitis and no prior steroid treat-
ment were initially excluded from the DEXA analysis. Demograph-
ic and clinical data of these patients were obtained by review of the 
medical records and by a questionnaire sent to all patients. In 
14 patients, a diagnosis of arthritis was documented in the ﬁ les; of 
these, 6 patients were classiﬁ ed as having seronegative spondylo-
arthropathy. There was 1 case of chronic hepatitis C and 1 case of 
primary sclerosing cholangitis, and 6 patients were diagnosed as 
having liver steatosis upon abdominal ultrasound. One case of 
Hashimoto thyroiditis and 1 patient with subclinical hyperthyroid-
ism were also included. 
 BMD Measurement 
 The BMD of the lumbar L2–L4 vertebrae and of the femoral 
neck was determined by standard DEXA at the Department of 
Rheumatology, University Hospital of Zürich. The results are ex-
pressed as either Z scores or T scores. Z scores indicate the number 
of SD from the normal sex- and age-speciﬁ c mean value. T scores 
were calculated in relation to sex-matched healthy young adults at 
the age of peak bone mass as the reference group. According to the 
World Health Organization criteria, osteoporosis was deﬁ ned as a 
T score below –2.5 SD, and osteopenia was deﬁ ned by a T score 
below –1 SD, but not more than 2.5 SD below the average. Data 
from the reference groups were supplied by the equipment manu-
facturer. 
 Statistics 
 The two-tailed Mann-Whitney U test was used to study the re-
lationship between Z scores and the following potential individual 
risk factors: diagnosis, sex, involvement of small bowel, weight loss, 
anemia, bowel resection, topic steroid treatment, azathioprine and 
methotrexate treatments, alcohol and nicotine consumption, and 
family history. Other risk factors were not studied because the sub-
groups were too small for a meaningful analysis. To determine the 
factors predictive of Z scores, stepwise regression with backward 
selection was performed with the following independent variables: 
diagnosis (CD vs. UC), sex, age, BMI, involvement of small bowels, 
bowel resection, family history of IBD, steroids (daily steroid dose, 
cumulative steroid dose, and topic steroid treatment), azathioprine 
and methotrexate treatments, as well as alcohol and nicotine con-
sumption. The two-tailed Mann-Whitney U test was also used to 
study the relationship between T scores and individual risk factors. 
To determine factors predictive of T scores, the patients were di-
vided into two groups (normal BMD with T scores above –1 SD 
versus pathological BMD with T scores below –1 SD), and stepwise 
logistic regression with backward selection was performed. p  ! 0.05 
was considered statistically signiﬁ cant. 
 Results 
 Characteristics of Patients Assessed by DEXA 
 The BMD was measured by DEXA in 88 IBD patients. 
DEXA was performed in 55 CD patients (30 male, 25 
female, mean age 39.0 years) and in 30 UC patients (19 
male, 11 female, mean age 44.2 years) with a disease 
 duration of 8.5  8 7.2 and 8.7  8 7.4 years, respectively 
( table 1 ). The BMD was additionally measured in 3 pa-
tients with indeterminate colitis. The small bowel was 
affected in 62% of the CD patients, whereas 10% of the 
UC patients had involvement of the terminal ileum. 
Small bowel resections had been performed in one third 
of the CD patients. Nearly all IBD patients had been 
treated with steroids at some stage of their disease (90% 
of the CD and 97% of the UC patients), with a higher cu-
mulative systemic steroid dose in UC than in CD patients 
(32.6 and 20.6 g, respectively). 
 Prevalence of Osteopenia and Osteoporosis in the IBD 
Patients 
 Pathological BMD (osteopenia or osteoporosis) was 
more frequently observed at the lumbar spine than at the 
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femoral neck (in 57 and 47% of the IBD patients, respec-
tively;  ﬁ g. 1 ). Osteoporosis, deﬁ ned as a T score below 
–2.5 SD, was found in 14% of the IBD patients (in 18% 
of the CD patients and in 10% of the UC patients) at the 
lumbar spine and in 5% of the IBD patients (in 4% of the 
CD patients and in 7% of the UC patients) at the femoral 
neck. Osteopenia, deﬁ ned as a T score between –1 and 
–2.5 SD, was present in 40% of the IBD patients. 
 Assessment of the Risk Factors for Low Z Scores 
 The distribution of the Z scores at lumbar spine and 
femoral neck among CD und UC patients is shown by 
box plots in  ﬁ gure 2 . The median values for CD patients 
were –1.15 at the lumbar spine and –0.6 at the femoral 
neck. The median values for UC patients were –0.8 at the 
lumbar spine and –0.2 at the femoral neck. To analyze 
the contribution of individual potential risk factors to low 
BMD values, we performed Mann-Whitney U tests. Pa-
tients who had undergone bowel resection showed a sig-
niﬁ cantly lower lumbar Z score than patients without 
bowel resections (p  ! 0.05). Other statistically signiﬁ cant 
individual risk factors were found neither at the lumbar 
spine nor at the femoral neck. We next performed step-
wise regression analysis to identify predictive factors for 
low Z scores. Patients who had undergone bowel resec-
tions or had been treated with topic steroids and azathio-
prine had a signiﬁ cantly increased risk of low lumbar Z 
scores. Additionally, patients with a low BMI and young-
 Table 1. Characteristics of 88 IBD patients assessed by DEXA (patients with indeterminate colitis not shown) 
IBD (n = 88) CD (n = 55) UC (n = 30)
Number of males (%) 50 (57) 30 (55) 19 (63)
Age, years (mean 8 SD) 40.6815.3 39.0814.7 44.2816.3
BMI, kg/m2 (mean 8 SD) 23.184.5 22.683.9 23.685.0
Disease duration, years (mean 8 SD) 8.387.2 8.587.2 8.787.4
Patients with ﬂ ares (mean 8 SD) 9.3810.0 9.3811.0 9.288.2
Small intestine involved (%) 38 (43) 34 (62) 3 (10)
Bowel resection (%)
Small bowel resection (%)
25 (28)
18 (20)
24 (44)
17 (31)
1 (3)
0 (0)
Steroid therapy (%) 82 (93) 50 (90) 29 (97)
Cumulative steroid dose, g (mean 8 SD)a 26.7846.8 20.6838.8 32.6856.7
Duration of steroid therapy, months (mean 8 SD) 40.8865.8 32.6861.9 47.9869.7
a 
 The steroid dose is expressed as grams of prednisone or as prednisone-equivalent dose.
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 Fig. 1. Prevalence of osteopenia and osteoporosis in 88 IBD pa-
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 Fig. 2. BMD expressed as Z scores in CD and UC 
patients. 
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er patients had a signiﬁ cantly increased risk of having low 
lumbar Z scores. The same predictive factors were found 
for femoral Z scores, except for bowel resection which did 
not reach statistical signiﬁ cance (p = 0.18;  table 2 ). 
 Assessment of the Risk Factors for Low T Scores 
 For analysis of the risk factors for low T scores, the 
patients were divided into two groups according to the 
WHO guidelines: (1) patients with normal T scores (above 
–1 SD) and (2) patients with osteopenia or osteoporosis 
(T score below –1 SD). The patients with a pathological 
lumbar T score were signiﬁ cantly younger, had a lower 
BMI, and had received more corticosteroid treatments 
(longer duration of steroid therapy and higher cumulative 
steroid doses). The steroid dose is expressed as grams of 
prednisone or prednisone-equivalent dose. These results 
are shown in  table 3 and in  ﬁ gure 3 .  Table 3 shows the 
median values of these risk factors in patients with nor-
mal and pathological BMD values. The box plots shown 
in  ﬁ gure 3 show the distribution of the cumulative steroid 
 Table 2. Predictive factors for Z scores, 
 assessed by stepwise regression analysis 
Signiﬁ cant
predictors
B regression
coefﬁ cient
p
Lumbar spine Z score
BMI 0.084 0.013
Age 0.025 0.005
Bowel resection –0.580 0.026
Topic steroids –0.531 0.028
Azathioprine –0.685 0.010
Femoral neck Z score
BMI 0.130 0.000
Age 0.020 0.009
Topic steroids –0.393 0.046
Azathioprine –0.551 0.012
 
 Table 3. Relationship between individual risk factors and T scores 
>1 SD below the mean, assessed by Mann-Whitney U test 
Signiﬁ cant risk factors T score
> –1 SD
T score
< –1 SD
p
Lumbar spine
BMI, kg/m2 23.1 21.4 0.048
Age, years 40.4 34.9 0.027
Duration of steroid therapy, months 9.0 18.5 0.034
Cumulative steroid dose, g 4.0 7.2 0.031
Femoral neck
BMI, kg/m2 23.6 20.8 0.005
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 Fig. 3. Cumulative steroid dose in patients 
with normal and pathological BMD. The 
steroid dose is expressed as grams of pred-
nisone or prednisone-equivalent dose. 
 Table 4. Predictive factors for T scores >1 SD below mean, as 
assessed by stepwise logistic regression 
Signiﬁ cant predictors Exp(B) p
Lumbar spine T score
Cumulative steroid dose 1.022 0.042
Topic steroids 2.917 0.038
Age 0.955 0.010
Bowel resection 3.088 0.059
Femoral neck T score
BMI 0.818 0.003
Topic steroids 2.679 0.051
Azathioprine 3.792 0.018
Exp(B) indicates the increase in the risk of a T score < –1 con-
ferred by the respective parameter (this can be interpreted as an 
odds ratio). In the case of the cumulative steroid dose, the Exp(B) 
value indicates a 1.022 greater risk of a T score < –1 with a cumu-
lative steroid dose of 1 g of prednisone or prednisone-equivalent 
dose; for 10 g cumulative steroids, this risk increases to 1.02210 
(= 1.24), for 40 g to 1.02240 (= 2.38), for 100 g to 1.022100
(= 8.8).
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doses in patients with normal and pathological lumbar 
BMD values. Stepwise regression analysis with backward 
selection revealed that a pathological lumbar T score in 
IBD patients was signiﬁ cantly correlated with a high cu-
mulative steroid dose, treatment with topic steroids, 
younger age, and bowel resection ( table 4 ). At the femoral 
neck, only low BMI values were signiﬁ cantly related to a 
pathological T score ( table 3 ). In stepwise regression an-
alysis, pathological femoral T scores were signiﬁ cantly 
correlated with low BMI, topic steroids and azathioprine 
treatment ( table 4 ). 
 Discussion 
 The main ﬁ ndings of this study can be summarized as 
follows: (1) osteopenia and osteoporosis show a high prev-
alence in IBD patients, with more than 50% being af-
fected, and (2) major risk factors for the development of 
osteopenia/osteoporosis are corticosteroid treatment and 
bowel resections; however, after exclusion of all other 
variables, disease activity per se appears to confer a rel-
evant independent risk. 
 We found a 14% prevalence of osteoporosis at the lum-
bar spine in our cohort of Swiss IBD patients. This is 
comparable with another Swiss study  [24] that recently 
reported a 9.7% prevalence of osteoporosis in IBD pa-
tients seen in specialist gastroenterology practice. Earlier 
studies reported an even higher prevalence of osteoporo-
sis in IBD patients of around 30%  [1, 18, 25] . The reason 
for this is not clear, since more patients were excluded in 
these studies compared to our investigation – one study 
 [25] excluded patients with bowel resections or a lifetime 
steroid dose  1 25 g, whereas another study  [1] excluded 
patients receiving treatment for osteoporosis or patients 
with severe malabsorption. It is of note, however, that the 
proportion of IBD patients with osteopenia was 40% in 
our study; this underlines the importance of carefully as-
sessing all IBD patients for BMD and initiating appropri-
ate treatment in those with a pathological BMD. Rele-
vance and efﬁ ciency of bisphosphonates in the treatment 
of these patients are subject of continued debate  [26–30] . 
Until further studies have clearly shown the clinical ben-
eﬁ t of bisphosphonates in osteoporosis associated with 
IBD, calcium and vitamin D should remain the baseline 
treatment in osteopenic and osteoporotic patients. 
 In our IBD cohort, in both CD and UC patients, the 
lumbar spine was found to be affected more often by a 
pathological BMD than the femoral neck. This ﬁ nding is 
surprising, because most studies have found a higher 
prevalence of osteoporosis at the femoral neck  [5, 18, 25, 
31–33] . There is no obvious reason for this discrepancy. 
It has been reported that treatment with corticosteroids 
results in bone loss, especially at trabecular bone sites  [34] 
such as the lumbar spine. There was, however, no evi-
dence for excessive steroid treatment in our cohort as 
compared with the other studies. 
 Multivariate regression analysis identiﬁ ed several pre-
dictive variables of reduced BMD at the lumbar spine. 
One predictive factor was the BMI. This relationship has 
been described in several previous studies  [17, 18, 35–
37] , and follow-up studies with repeated BMD measure-
ments have shown that a reduction in BMI leads to bone 
loss  [20, 38] . Furthermore, young age was identiﬁ ed as a 
predictive variable for both low Z and T scores, although 
the regression coefﬁ cients were low (0.020 and 0.025 for 
femoral and lumbar Z scores, respectively). This suggests 
that, at least in our cohort, younger IBD patients had a 
mildly elevated risk of osteoporosis than older patients. 
This could be due to a more active disease in young pa-
tients, leading to osteoporosis via circulating cytokines 
 [39] which affect osteoclast  [40] and osteoblast function 
 [41] . This observation is in agreement with results of a 
study showing that IBD patients younger than 18 years 
at the time of diagnosis are at risk of osteoporosis  [32] . 
 The hypothesis that the disease activity is an indepen-
dent risk factor for the development of osteoporosis is 
supported by the ﬁ nding that topic steroids and azathio-
prine were signiﬁ cant predictors of BMD. So far, no det-
rimental effect of azathioprine on BMD has been shown. 
We assume that azathioprine is negatively correlated with 
BMD, because it is used in IBD patients with high inﬂ am-
matory activity requiring additional immunosuppressive 
medication. Contrary to azathioprine, methotrexate 
treatment was not found to be correlated with BMD 
which may be due to the low number of patients treated: 
whereas 61 patients (69%) were treated with azathio-
prine, only 8 patients (9%) had received methotrexate. 
The negative effect of topic steroid treatment on BMD 
could in part be attributable to a systemic effect of local 
steroids. 
 The deleterious effect of systemic steroids on BMD is 
supported by the ﬁ nding that patients with a pathological 
BMD had received a more intense steroid treatment 
(higher cumulative steroid dose and longer duration of 
steroid therapy). This conﬁ rms previous observations 
showing that systemic corticosteroids are a risk factor for 
osteoporosis in CD patients  [2] . In particular, high life-
time systemic steroid doses  1 10 g have been reported to 
be correlated with a low BMD  [12, 14] . 
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 Multivariate analysis further revealed a history of 
bowel resections as a signiﬁ cant predictive variable of low 
BMD values. This issue is controversial in the literature, 
since some studies have described bowel resections as a 
risk factor  [14, 18] , whereas others have not found a cor-
relation  [12, 42] . In our cohort, patients with a history of 
bowel resection had a threefold risk of a pathological 
BMD at the lumbar spine. One possible explanation for 
this relationship is that bowel resections lead to a malab-
sorptive state, e.g., for vitamin D  [43] or vitamin K  [44] . 
The role of the nutritional status in the development of 
osteopenia/osteoporosis is supported by the ﬁ nding that 
a low BMI is a risk factor for reduced BMD, as described 
above. An alternative explanation, however, is that bow-
el resections are a sign of severe disease, leading to sys-
temic inﬂ ammation and complications which necessitate 
a surgical intervention. 
 One limitation of our study is that we did not apply 
strict exclusion criteria, in order to include a broad spec-
trum of IBD patients in our analyses. Only patients with 
isolated proctitis and no prior steroid treatment were ini-
tially excluded from the DEXA analysis. Data from BMD 
measurements were available for 88 patients (64%) in our 
cohort. When patients assessed by DEXA are compared 
with the total IBD cohort, the mean disease duration was 
longer (8.3 vs. 7.6 years), more patients had received ste-
roid therapy (93 vs. 82%), and more patients had a his-
tory of bowel resection (28 vs. 24%). A selection bias, 
which could affect prevalence reportings in this study, 
cannot be excluded with certainty. Moreover, this study 
cannot prove that corticosteroids or bowel resections are 
causes of osteoporosis in IBD patients. The regression 
analyses performed are only able to provide correlative 
evidence for the involvement of different risk factors in 
the development of osteoporosis in IBD patients. 
 In summary, our results show that the prevalence of 
osteopenia and osteoporosis is high in a Swiss cohort of 
IBD patients. Major risk factors for low BMD values were 
corticosteroid treatment and a history of bowel resection, 
although a relevant risk is conferred by disease activity 
per se, irrespective of other variables analyzed. Moreover, 
the high prevalence of osteopenia reported in this study 
underlines the importance of monitoring by DEXA not 
only high-risk patients, but all IBD patients, and of initi-
ating appropriate treatment in patients with low BMD 
values. Whether antiresorptive therapy with bisphospho-
nates in addition to calcium and vitamin D helps to pre-
vent fractures in IBD patients with a low BMD remains 
to be evaluated. 
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